Business
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
BEDFORD, Mass., February 04, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday,
About this update from Stoke Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":223,"url":"https://media.zenfs.com/en/business-wire.com/d3acbc34193d2fb593533f5d55902b6a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nOiXkCgR37iTB8he10rVZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d3acbc34193d2fb593533f5d55902b6a","width":480,"height":223}},"lazy":false},{"type":"text","content":"BEDFORD, Mass., February 04, 2026--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET.","length":552,"tagName":"p"},{"type":"text","content":"A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.","length":189,"tagName":"p"},{"type":"text","content":"About Stoke Therapeutics","length":24,"tagName":"p"},{"type":"text","content":"Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit ht...